Compare Apartment Investment and Management Co (AIV) vs Amylx Pharmaceuticals Inc (AMLX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Apartment Investment and Management Co vs Amylx Pharmaceuticals Inc — how do they compare? Apartment Investment and Management Co trades at $2.61 (market cap $376.16M), while Amylx Pharmaceuticals Inc trades at $23.6 (market cap $2.64B). The key difference: Amylx Pharmaceuticals Inc is far larger — about 7× Apartment Investment and Management Co's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Apartment Investment and Management Co nearer its low. Which is the better fit depends on your goals.
| AIV | AMLX | |
|---|---|---|
Market Cap | $376.16M | $2.64B |
Sector | Real Estate | Health |
52-Week High | $7.93 | $24.19 |
52-Week Low | $2.59 | $7.82 |
Enterprise Value | $738.32M | $2.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AIV trades at $2.605, down 0.57% today, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q1 and Q4 2025 but missing in Q2 and Q3. Despite a net income margin of 400.05% in 2025, revenue declined to $138.49M from $209M in 2024. Analyst consensus shows 1 Buy and 2 Hold ratings, indicating cautious optimism. A dividend of $1.30 is scheduled for H1-2026.
Outlook: AIV's high profitability metrics and undervalued P/B ratio of 0.76 present potential upside, but declining revenue and bearish technicals pose risks. Investment opportunity lies in dividend yield and earnings recovery, while key risks include revenue volatility and competitive pressures in real estate.
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Apartment Investment and Management Co
Apartment Investment & Management Co is a self-managed real estate investment trust. It is focused on property development, redevelopment and various other value-creating investment strategies, targeting the U.S multifamily market. Its operating segments are Development and Redevelopment
Read more on AIV →About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →
